Arrowhead Pharmaceuticals Inc (ARWR)
24.77
-0.23
(-0.92%)
USD |
NASDAQ |
May 17, 16:00
24.77
0.00 (0.00%)
Pre-Market: 20:00
Arrowhead Pharmaceuticals Cash from Operations (Quarterly): -92.38M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -92.38M |
December 31, 2023 | -117.84M |
September 30, 2023 | -25.26M |
June 30, 2023 | -21.45M |
March 31, 2023 | -31.67M |
December 31, 2022 | -75.52M |
September 30, 2022 | -68.74M |
June 30, 2022 | -68.82M |
March 31, 2022 | 62.73M |
December 31, 2021 | -61.31M |
September 30, 2021 | -24.03M |
June 30, 2021 | -29.61M |
March 31, 2021 | 263.87M |
December 31, 2020 | -38.92M |
September 30, 2020 | -11.26M |
June 30, 2020 | -33.43M |
March 31, 2020 | -27.58M |
December 31, 2019 | -23.53M |
September 30, 2019 | 13.81M |
June 30, 2019 | 10.53M |
March 31, 2019 | -19.59M |
December 31, 2018 | 168.28M |
September 30, 2018 | -2.680M |
June 30, 2018 | -14.41M |
March 31, 2018 | -15.44M |
Date | Value |
---|---|
December 31, 2017 | -14.69M |
September 30, 2017 | -9.204M |
June 30, 2017 | -10.41M |
March 31, 2017 | -14.33M |
December 31, 2016 | 10.00M |
September 30, 2016 | -10.18M |
June 30, 2016 | -18.35M |
March 31, 2016 | -14.75M |
December 31, 2015 | -21.15M |
September 30, 2015 | -12.02M |
June 30, 2015 | -13.12M |
March 31, 2015 | -16.37M |
December 31, 2014 | -24.20M |
September 30, 2014 | -10.92M |
June 30, 2014 | -9.776M |
March 31, 2014 | -7.698M |
December 31, 2013 | -7.022M |
September 30, 2013 | -5.394M |
June 30, 2013 | -5.335M |
March 31, 2013 | -4.467M |
December 31, 2012 | -3.838M |
September 30, 2012 | -4.588M |
June 30, 2012 | -3.889M |
March 31, 2012 | -4.158M |
December 31, 2011 | -2.706M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-117.84M
Minimum
Dec 2023
263.87M
Maximum
Mar 2021
-20.02M
Average
-28.60M
Median
Cash from Operations (Quarterly) Benchmarks
89bio Inc | -39.72M |
Madrigal Pharmaceuticals Inc | -149.16M |
Viking Therapeutics Inc | -6.134M |
Akero Therapeutics Inc | -35.14M |
Sagimet Biosciences Inc | -6.208M |
Cash from Operations (Quarterly) Related Metrics
Cash from Investing (Quarterly) | -268.94M |
Cash from Financing (Quarterly) | 430.78M |
Free Cash Flow | -470.16M |
Free Cash Flow Per Share (Quarterly) | -1.026 |
Free Cash Flow Yield | -17.06% |